Fluorescent membrane potential assay for drug screening on Kv10.1 channel: identification of BL-1249 as a channel activator
暂无分享,去创建一个
[1] A. Anaya-Hernández,et al. The Kv10.1 Channel: A Promising Target in Cancer , 2022, International journal of molecular sciences.
[2] E. Luis,et al. Role of gamma radiation on functional expression of the voltage-gated potassium channel Kv10.1 and its importance in the radiobiological response. , 2022, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.
[3] P. Slesinger,et al. Comparison of K+ Channel Families. , 2021, Handbook of experimental pharmacology.
[4] A. Hernández-Cruz,et al. Thallium-sensitive fluorescent assay reveals loperamide as a new inhibitor of the potassium channel Kv10.1 , 2021, Pharmacological Reports.
[5] A. Mathie,et al. Pharmacological Approaches to Studying Potassium Channels. , 2021, Handbook of experimental pharmacology.
[6] J. Bednenko,et al. Therapeutic Antibodies Targeting Potassium Ion Channels. , 2021, Handbook of experimental pharmacology.
[7] L. Pardo,et al. Overcoming challenges of HERG potassium channel liability through rational design: Eag1 inhibitors for cancer treatment , 2021, Medicinal research reviews.
[8] L. Pardo,et al. The EAG Voltage-Dependent K+ Channel Subfamily: Similarities and Differences in Structural Organization and Gating , 2020, Frontiers in Pharmacology.
[9] A. Rodríguez-Menchaca,et al. Chloroquine inhibits tumor-related Kv10.1 channel and decreases migration of MDA-MB-231 breast cancer cells in vitro. , 2019, European journal of pharmacology.
[10] C. Lindsley,et al. Towards a TREK-1/2 (TWIK-Related K+ Channel 1 and 2) dual activator tool compound: Multi-dimensional optimization of BL-1249. , 2019, Bioorganic & medicinal chemistry letters.
[11] B. L. de Groot,et al. A pharmacological master key mechanism that unlocks the selectivity filter gate in K+ channels , 2019, Science.
[12] M. Stacey,et al. Emerging Roles of the Membrane Potential: Action Beyond the Action Potential , 2018, Front. Physiol..
[13] N. Prevarskaya,et al. Ion Channels in Cancer: Are Cancer Hallmarks Oncochannelopathies? , 2018, Physiological reviews.
[14] C. Osipo,et al. Preclinical study of a Kv11.1 potassium channel activator as antineoplastic approach for breast cancer , 2017, Oncotarget.
[15] Roderick MacKinnon,et al. Cryo-EM Structure of the Open Human Ether-à-go-go-Related K+ Channel hERG , 2017, Cell.
[16] L. Pardo,et al. The electric fence to cell‐cycle progression: Do local changes in membrane potential facilitate disassembly of the primary cilium? , 2017, BioEssays : news and reviews in molecular, cellular and developmental biology.
[17] Roderick MacKinnon,et al. Structure of the voltage-gated K+ channel Eag1 reveals an alternative voltage sensing mechanism , 2016, Science.
[18] L. Pardo,et al. Cyclic expression of the voltage‐gated potassium channel KV10.1 promotes disassembly of the primary cilium , 2016, EMBO reports.
[19] L. Pardo,et al. Analysis of the expression of Kv10.1 potassium channel in patients with brain metastases and glioblastoma multiforme: impact on survival , 2015, BMC Cancer.
[20] Michael X. Zhu,et al. Membrane potential modulates plasma membrane phospholipid dynamics and K-Ras signaling , 2015, Science.
[21] L. Pardo,et al. Potassium channels in cell cycle and cell proliferation , 2014, Philosophical Transactions of the Royal Society B: Biological Sciences.
[22] S. Gentile,et al. Potassium channel activation inhibits proliferation of breast cancer cells by activating a senescence program , 2013, Cell Death and Disease.
[23] S. Hahn,et al. Effects of fluoxetine on cloned Kv4.3 potassium channels , 2013, Brain Research.
[24] Linlang Guo,et al. MiR-296-3p regulates cell growth and multi-drug resistance of human glioblastoma by targeting ether-à-go-go (EAG1). , 2013, European journal of cancer.
[25] L. Pardo,et al. Eag1 Expression Interferes with Hypoxia Homeostasis and Induces Angiogenesis in Tumors , 2008, Journal of Biological Chemistry.
[26] H. Neels,et al. Relevant Issues in the Monitoring and the Toxicology of Antidepressants , 2008 .
[27] L. Pardo,et al. Eag1 potassium channels as markers of cervical dysplasia. , 2007, Oncology reports.
[28] C. Bever,et al. Potassium channel blockers and openers as CNS neurologic therapeutic agents. , 2007, Recent patents on CNS drug discovery.
[29] L. Pardo,et al. Overexpression of Eag1 potassium channels in clinical tumours , 2006, Molecular Cancer.
[30] Haruhiko Abe,et al. Blockade of HERG cardiac K+ current by antifungal drug miconazole , 2005, British journal of pharmacology.
[31] L. Pardo,et al. Ether à go-go Potassium Channels as Human Cervical Cancer Markers , 2004, Cancer Research.
[32] Dierk Thomas,et al. The antidepressant drug fluoxetine is an inhibitor of human ether-a-go-go-related gene (HERG) potassium channels. , 2002, The Journal of pharmacology and experimental therapeutics.
[33] Yann Hode,et al. Brain Pharmacokinetics and Tissue Distribution In Vivo of Fluvoxamine and Fluoxetine by Fluorine Magnetic Resonance Spectroscopy , 2000, Neuropsychopharmacology.
[34] K. Lawson,et al. Potassium channel openers as potential therapeutic weapons in ion channel disease. , 2000, Kidney international.
[35] L. Pardo,et al. Oncogenic potential of EAG K+ channels , 1999, The EMBO journal.
[36] B. Sakmann,et al. Single-channel currents recorded from membrane of denervated frog muscle fibres , 1976, Nature.
[37] H. Curtis,et al. Membrane resting and action potentials from the squid giant axon , 1942 .
[38] I. Vetter,et al. High-Throughput Fluorescence Assays for Ion Channels and GPCRs. , 2020, Advances in experimental medicine and biology.
[39] A. Verkhratsky,et al. History of electrophysiology and the patch clamp. , 2014, Methods in molecular biology.
[40] J. Camacho,et al. Astemizole: an old anti-histamine as a new promising anti-cancer drug. , 2011, Anti-cancer agents in medicinal chemistry.
[41] S. Hahn,et al. Open channel block of Kv3.1 currents by fluoxetine. , 2008, Journal of pharmacological sciences.
[42] A. A. Al-badr,et al. Miconazole nitrate: comprehensive profile. , 2005, Profiles of drug substances, excipients, and related methodology.